why choose us

First received: September 09, 2023

Clinical Trial: Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

Study Status: Completed

Recruit Status: RECRUITING

Condition: Healthy Participants

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of AK006 in He

Brief Summary: This is a Phase 1, double-blind, randomized, placebo-controlled study that will evaluate the safety, pharmacokinetics (PK), immunogenicity (immune response), and explore the clinical activity of single and multiple ascending doses of AK006 when administered intravenously (IV) to healthy participants and participants with chronic spontaneous urticaria (CSU).

Read more